SELLAS Life Sciences Group (SLS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Proposal 2 now seeks ratification of Baker Tilly as the independent registered public accounting firm for 2025, following the merger with Moss Adams.
Votes previously cast for or against Proposal 2 will be counted as votes for or against Baker Tilly's ratification.
No new proxy cards or voting instructions are required unless shareholders wish to change their vote.
Proxy materials are available electronically, and shareholders can vote by Internet, phone, or mail until June 16, 2025.
Shareholders may also vote during the annual meeting if they are stockholders of record and follow the provided instructions.
Audit committee and external auditor matters
Moss Adams resigned as auditor after merging with Baker Tilly; Baker Tilly was appointed as the new auditor for 2025.
Moss Adams' audit reports for 2023 and 2024 had no adverse opinions but included a going concern explanatory paragraph.
No disagreements or reportable events occurred between the company and Moss Adams during the relevant periods.
Moss Adams was provided a copy of the Form 8-K and its response was filed as Exhibit 16.1.
The company did not consult Baker Tilly on accounting matters prior to their appointment.
Risk oversight and compliance
The audit committee managed the transition between audit firms and ensured regulatory compliance in the process.
Shareholders were informed of the auditor change and voting implications through a supplement and SEC filings.
Latest events from SELLAS Life Sciences Group
- REGAL Phase 3 interim analysis in AML will guide next steps after IDMC review in January 2025.SLS
Study Update11 Jan 2026 - Late-stage cancer drug developer registers resale of 19.7M shares tied to new warrant inducement.SLS
Registration Filing16 Dec 2025 - Six key proposals, including director elections and compensation, headline the 2025 virtual meeting.SLS
Proxy Filing2 Dec 2025 - Key votes include director elections, auditor ratification, and ESPP share increase.SLS
Proxy Filing2 Dec 2025 - Net loss narrowed, cash reserves grew, and key oncology trials advanced amid ongoing risks.SLS
Q3 202512 Nov 2025 - GPS and SLS009 advance as differentiated AML therapies, supported by strong data and financing.SLS
R&D Day 20255 Nov 2025 - Net loss narrowed, clinical milestones approach, but liquidity and funding concerns remain.SLS
Q3 202413 Oct 2025 - Net loss narrowed, but new funding is needed as clinical programs advance.SLS
Q2 202512 Aug 2025 - Reduced losses, strong clinical data, and a $21M capital raise amid ongoing liquidity risks.SLS
Q2 202413 Jun 2025